Quantification of Peripheral Blood iNKTs After Allogeneic Stem Cell Transplantation
- Sponsor
- University Hospital Pilsen
- Study ID
- NCT07570407
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Acute Myeloid Leukemia
- Allogeneic HSCT
- GvHD
- Posttransplant Complications
- Relapse
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- blood draw — DIAGNOSTIC_TESTBlood draw for diagnostic test
Study Details
The transplantation of allogeneic haematopoietic stem cells (HSCs) can lead to serious complications after transplantation, such as graft-versus-host disease (GvHD), infections and relapse due to immunosuppression. Invariant NKT cells (iNKT cells) play a pivotal role in modulating the immune response and have been demonstrated to be instrumental in the pathogenesis of GvHD, cytomegalovirus (CMV) infection, and relapse. Their levels are associated with the development of these complications. This multicentre study aims to test the feasibility of standardising iNKT cell monitoring and to investigate the association between iNKT cell levels and post-transplant complications.
Key Dates
- Start date
- May 1, 2026
- Status verified
- Apr 2026
- Primary completion
- Dec 31, 2028
- Completion
- Jan 31, 2029
Study Design
- Enrollment
- 75 participants (estimated)
Arms
- Arm: HSCT patientsPatients who have undergone allogeneic hematopoietic cell transplantation and have been diagnosed with acute myeloid leukemia.
Primary Outcome Measure
Detection of peripheral blood iNKTs after HSCT using flow cytometry [ Time Frame: Day 30, day 60, day 90 ]
Central Contacts
- Monika Holubová, MD, Ph.D.+420 377 103 991
- Lenka Lukášová, MD, Ph.D.+420 377 103 871
Related Studies
- Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic SyndromeRecruiting · University of Rochester · Rochester, New York
- Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid LeukemiaPHASE2 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas
- PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid LeukemiaPHASE1 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas
- Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid TumorsPHASE1 · Recruiting · University of Wisconsin, Madison · Madison, Wisconsin